Birdwatch Note
2024-11-11 21:17:45 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
La métanalyse de référence a montré que l'hydroxychloroquine entrainait une surmortalité de 11% dans le cas de son utilisation dans le traitement du Covid-19. Ce qui est présenté ici comme un remède est donc de nature à augmenter la mortalité. https://doi.org/10.1038/s41467-021-22446-z
Written by 6754891D631CCC94EB888675B4558BF18E3E6CD8D67F94BD525FC8222BC50B02
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1566831158016544773
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1856083921684906485
- noteId - 1856083921684906485
- participantId -
- noteAuthorParticipantId - 6754891D631CCC94EB888675B4558BF18E3E6CD8D67F94BD525FC8222BC50B02 Participant Details
- createdAtMillis - 1731359865958
- tweetId - 1566831158016544773
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- La métanalyse de référence a montré que l'hydroxychloroquine entrainait une surmortalité de 11% dans le cas de son utilisation dans le traitement du Covid-19. Ce qui est présenté ici comme un remède est donc de nature à augmenter la mortalité. https://doi.org/10.1038/s41467-021-22446-z
Note Ratings
| rated at | rated by | |
| 2024-11-12 00:00:29 -0600 | Rating Details | |
| 2024-11-12 00:00:14 -0600 | Rating Details | |
| 2024-11-11 15:28:02 -0600 | Rating Details | |
| 2024-11-11 15:18:37 -0600 | Rating Details | |
| 2024-11-29 03:19:52 -0600 | Rating Details | |
| 2024-11-23 06:02:50 -0600 | Rating Details | |
| 2024-11-23 03:26:00 -0600 | Rating Details | |
| 2024-11-21 00:34:09 -0600 | Rating Details | |
| 2024-11-21 15:13:50 -0600 | Rating Details | |
| 2024-11-24 07:30:47 -0600 | Rating Details | |
| 2024-12-21 05:06:37 -0600 | Rating Details | |
| 2024-12-18 02:35:25 -0600 | Rating Details | |
| 2024-12-25 01:14:29 -0600 | Rating Details | |
| 2024-12-17 07:48:11 -0600 | Rating Details | |
| 2025-01-18 16:59:48 -0600 | Rating Details | |
| 2025-01-18 13:41:11 -0600 | Rating Details | |
| 2025-01-05 21:58:17 -0600 | Rating Details | |
| 2024-12-24 15:50:24 -0600 | Rating Details | |
| 2024-12-18 14:57:14 -0600 | Rating Details | |
| 2025-01-17 08:25:25 -0600 | Rating Details |